A	B	C
1	Main
2		Brand	VX-880
3		Indication	Type 1 Diabetes
4		MOA	stem cell-derived, fully differentiated pancreatic islet cell replacement therapy
5		Administration	infusion into hepatic portal vein with immunosuppression
6		Clinical Trials
7			Phase I/II n=17 single-arm, open-label
8			Part A n=2 half dose
9			P1 40.1% time-in-range to 99.9% with insulin independence at day 270
10			P2 35.9% time-in-range to 51.9% with -30% insulin use at day 150
11			Part B n=5
12			Part C n=10